Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.460
-0.030 (-2.01%)
At close: Feb 21, 2025, 4:00 PM
1.450
-0.010 (-0.67%)
After-hours: Feb 21, 2025, 6:48 PM EST
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Lishan Aklog |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 917 813 1828 |
| Website | luciddx.com |
Stock Details
| Ticker Symbol | LUCD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001799011 |
| CUSIP Number | 54948X109 |
| ISIN Number | US54948X1090 |
| Employer ID | 82-5488042 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Michael Adam Gordon | General Counsel and Secretary |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Joseph Willis M.D. | Co-founder and Strategic Advisor |
| Dr. Amitabh Chak M.D. | Co-Founder and Strategic Advisor |
| Helen Moinova Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Brian J. deGuzman M.D. | Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
| Matthew Riley | Director of Investor Relations |
| Dr. Deepika A. Lakhani Ph.D. | Senior Vice President, Chief Regulatory and Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 31, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 31, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 6, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |